Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.

Mazzio EA, Close F, Soliman KF.

Int J Mol Sci. 2011 Jan 17;12(1):506-69. doi: 10.3390/ijms12010506. Review.

2.

Protective and toxic roles of dopamine in Parkinson's disease.

Segura-Aguilar J, Paris I, Muñoz P, Ferrari E, Zecca L, Zucca FA.

J Neurochem. 2014 Jun;129(6):898-915. doi: 10.1111/jnc.12686. Epub 2014 Mar 18. Review.

3.

Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.

Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL.

Brain. 2005 Nov;128(Pt 11):2654-64. Epub 2005 Jul 6.

PMID:
16000336
4.

Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.

Büeler H.

Exp Neurol. 2009 Aug;218(2):235-46. doi: 10.1016/j.expneurol.2009.03.006. Epub 2009 Mar 18. Review.

PMID:
19303005
5.

Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.

Schintu N, Frau L, Ibba M, Garau A, Carboni E, Carta AR.

Neurotox Res. 2009 Aug;16(2):127-39. doi: 10.1007/s12640-009-9061-x. Epub 2009 May 27.

PMID:
19526289
6.

Modifications of the iron-neuromelanin system in Parkinson's disease.

Fasano M, Bergamasco B, Lopiano L.

J Neurochem. 2006 Feb;96(4):909-16. Epub 2006 Jan 17. Review.

7.

Drug treatment of Parkinson's disease. Time for phase II.

Drukarch B, van Muiswinkel FL.

Biochem Pharmacol. 2000 May 1;59(9):1023-31.

PMID:
10704931
8.

The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.

Zuo L, Motherwell MS.

Gene. 2013 Dec 10;532(1):18-23. doi: 10.1016/j.gene.2013.07.085. Epub 2013 Aug 15. Review.

PMID:
23954870
9.

Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.

Perfeito R, Cunha-Oliveira T, Rego AC.

Free Radic Biol Med. 2013 Sep;62:186-201. doi: 10.1016/j.freeradbiomed.2013.05.042. Epub 2013 Jun 3. Review.

PMID:
23743292
10.

Trib3 Is Elevated in Parkinson's Disease and Mediates Death in Parkinson's Disease Models.

Aimé P, Sun X, Zareen N, Rao A, Berman Z, Volpicelli-Daley L, Bernd P, Crary JF, Levy OA, Greene LA.

J Neurosci. 2015 Jul 29;35(30):10731-49. doi: 10.1523/JNEUROSCI.0614-15.2015.

11.

[The role of neuromelanin in Parkinson's disease--new concepts].

Stepień K, Dzierzega-Lecznar A, Tam I.

Wiad Lek. 2007;60(11-12):563-9. Review. Polish.

PMID:
18540183
12.

Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions.

Elstner M, Müller SK, Leidolt L, Laub C, Krieg L, Schlaudraff F, Liss B, Morris C, Turnbull DM, Masliah E, Prokisch H, Klopstock T, Bender A.

Mol Brain. 2011 Dec 21;4:43. doi: 10.1186/1756-6606-4-43.

13.

Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.

Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K, Takahashi S, Ehara S, Terayama Y, Sakai A.

Neuroreport. 2006 Jul 31;17(11):1215-8.

PMID:
16837857
14.

3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease.

Ogisu K, Kudo K, Sasaki M, Sakushima K, Yabe I, Sasaki H, Terae S, Nakanishi M, Shirato H.

Neuroradiology. 2013 Jun;55(6):719-24. doi: 10.1007/s00234-013-1171-8. Epub 2013 Mar 23.

PMID:
23525598
15.

Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.

Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH.

Neurobiol Dis. 2009 Sep;35(3):385-98. doi: 10.1016/j.nbd.2009.05.023. Epub 2009 Jun 6.

PMID:
19505575
16.

Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons.

Kooncumchoo P, Sharma S, Porter J, Govitrapong P, Ebadi M.

J Mol Neurosci. 2006;28(2):125-41.

PMID:
16679553
17.

Multiple antioxidants in the prevention and treatment of Parkinson's disease.

Prasad KN, Cole WC, Kumar B.

J Am Coll Nutr. 1999 Oct;18(5):413-23. Review.

PMID:
10511322
18.

Metals, oxidative stress and neurodegenerative disorders.

Jomova K, Vondrakova D, Lawson M, Valko M.

Mol Cell Biochem. 2010 Dec;345(1-2):91-104. doi: 10.1007/s11010-010-0563-x. Epub 2010 Aug 22. Review.

PMID:
20730621
19.
20.

Quantitative expression proteomics and phosphoproteomics profile of brain from PINK1 knockout mice: insights into mechanisms of familial Parkinson's disease.

Triplett JC, Zhang Z, Sultana R, Cai J, Klein JB, Büeler H, Butterfield DA.

J Neurochem. 2015 Jun;133(5):750-65. doi: 10.1111/jnc.13039. Epub 2015 Mar 1.

Supplemental Content

Support Center